Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2013

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver

December 2, 2013 – SAN DIEGO (GLOBE NEWSWIRE) - Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…

Related to: Conatus Pharmaceuticals

Gilde Healthcare closes €145 million ($200 million) transatlantic growth capital fund

November 26, 2013 – Utrecht (The Netherlands) and Cambridge (USA, MA) – Gilde Healthcare, the specialist investment firm, today announces the final close of its €145 million ($200 million) transatlantic growth capital fund, Gilde Healthcare III (GHC III). The new fund targets investment in innovative…

BG Medicine Announces FDA 510(k) Clearance of its Galectin-3 Test

November 23, 2013 – WALTHAM, MA (BUSINESS WIRE)— BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed…

Related to: BG Medicine

Acacia Pharma Initiates Phase 2 study with APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)

October 30, 2013 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem…

Related to: Acacia Pharma

Acacia Pharma announces positive Phase II results for Xerostomia in advanced cancer

October 15, 2013 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515…

Related to: Acacia Pharma

Conatus Pharmaceuticals Initiates Phase 2b Trial in Acute-on-Chronic Liver Failure (ACLF) Patients

September 11, 2013 – SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients…

Related to: Conatus Pharmaceuticals

Conatus Pharmaceuticals Dosed First Patient in Phase 2 Trial in Severe Alcoholic Hepatitis

September 10, 2013 – SAN DIEGO - Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of dosing in the Phase 2 clinical trial of emricasan in patients with severe alcoholic…

Related to: Conatus Pharmaceuticals

Acacia Pharma Announces £15M ($23.5M) Series B Financing

September 3, 2013 – Cambridge, UK – Acacia Pharma, the pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million ($23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond…

Related to: Acacia Pharma

Agendia - 'High Risk' Breast Cancer Patients with Unusual Hormone Receptors May Be Undertreated

August 27, 2013 – Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence IRVINE, CA and AMSTERDAM, THE NETHERLANDS - Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset of breast cancer patients whose standard…

Related to: Agendia

Moximed Completes Enrollment of KineSpring System US SOAR Study in Patients with Knee Osteoarthritis

August 21, 2013 – HAYWARD, California - Moximed®, Inc. announced today that enrollment has been completed in its US-based SOAR clinical study. Patients enrolled in the SOAR clinical study were treated with the KineSpring® System, an implantable medical spring that works by unloading weight in the knee…

Related to: Moximed

Succesful exit Gilde following sale of participation in Dutch biopharmaceutical company ProFibrix

August 7, 2013 – Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare (‘Gilde’), the growth capital firm specialized in healthcare, announces it has sold its minority stake in biopharmaceutical company ProFibrix (Leiden, the Netherlands) to US listed pharmaceutical company The Medicines…

Related to: ProFibrix

Conatus Pharmaceuticals announces IPO at NASDAQ

July 25, 2013 – SAN DIEGO -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biopharmaceutical company focused on the development and commercialization of novel medicines to treat liver disease, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a…

Related to: Conatus Pharmaceuticals

Santaris Pharma A/S signs partnership with RaNA Therapeutics, Inc.

July 11, 2013 – Hørsholm, Denmark/San Diego, California & Cambridge, Massachusetts — Santaris Pharma A/S and RaNA Therapeutics, Inc. announced that they have signed an agreement whereby RaNA gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the…

Related to: Santaris Pharma

UniQure signs collaboration with Chiesi Farmaceutici SpA and announces USD 58 million in new funding

July 10, 2013 – Amsterdam, the Netherlands — uniQure B.V. announced it has signed collaboration agreements with Chiesi Farmaceutici SpA for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia…

Related to: uniQure

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration

June 26, 2013 – COPENHAGEN, Denmark – Symphogen, ­­­­­­a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives…

Related to: Symphogen

Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering

June 14, 2013 – San Diego, CA – Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the…

Related to: Conatus Pharmaceuticals

The Medicines Company Signs Agreement to Acquire ProFibrix

June 4, 2013 – Leiden, the Netherlands, Parsippany, NJ and Seattle, WA - The Medicines Company (NASDAQ: MDCO) and ProFibrix B.V. today announced an agreement for The Medicines Company to purchase all of the outstanding capital stock of ProFibrix B.V. subject to The Medicines Company’s satisfactory…

Related to: ProFibrix

Agendia Appoints Peter W. Schineller as Chief Commercial Officer

June 3, 2013 – Veteran Diagnostics and Biotech Executive to Lead Global Commercialization IRVINE, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer.  In this newly created position,…

Related to: Agendia

Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture

June 2, 2013 – ASCO Presentation and Poster on Sym004 in mCRC and SCCCHN Copenhagen, Denmark – Symphogen, ­­­­­­a private biopharmaceutical company developing recombinant antibody mixtures, announced today at the 2013 Annual Meeting of the American Society of Clinical Oncology ( ASCO) the results…

Related to: Symphogen

Gilde Healthcare Expands Team by Appointing Bob Silverman as Operational Partner

May 27, 2013 – Utrecht, the Netherlands and Boston, USA – Gilde Healthcare, an investment firm focused on private healthcare companies, today announced that Bob Silverman has been appointed as Operational Partner. His main focus will be on supporting Gilde’s investments in diagnostics and medical…

Related to: mtm laboratories

Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results

May 2, 2013 – Revenues Continue to Ramp in 2013 IRVINE, CA – Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone.  The MammaPrint test analyzes 70 key genes…

Related to: Agendia

Symphogen Expands Previous Private Equity Round, Reaching a Total of €141 million (USD 185 million)

May 2, 2013 – Copenhagen, Denmark – Symphogen, ­­­­­­a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced €100 million financing attaining a total of a €141 million placement of preferred stock to a…

Related to: Symphogen

Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin®

April 18, 2013 – Freising, Germany – Pieris AG has achieved the second milestone for the first of two programs in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment,…

Related to: Pieris Pharmaceuticals Inc.

Santaris announces Strategic Alliance with Bristol-Myers Squibb

April 17, 2013 – Hørsholm, Denmark / San Diego, California — Santaris Pharma A/S, a privately held biopharmaceutical company announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug…

Related to: Santaris Pharma

Pieris and Sanofi Broaden Existing Collaboration

April 10, 2013 – Deal Expanded to Include Additional Multispecific Anticalins Freising, Germany – Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin program. Under the existing framework of the…

Related to: Pieris Pharmaceuticals Inc.

Symphogen Presents New pan-HER data at Annual AACR Meeting

April 10, 2013 – COPENHAGEN, Denmark - Symphogen today at the Annual Meeting of the American Association for Cancer Research in Washington DC, presented new preclinical data suggesting that a mixture of antibodies, known as pan-HER, that simultaneously inhibits EGFR, HER2 and HER3, is superior to…

Related to: Symphogen

ProFibrix Completes Patient Enrolment in Pivotal Phase III with FibrocapsTM and Reports Positive

April 4, 2013 – Company remains on track for 2013 filings in US and Europe LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in innovative bioactive products to stop bleeding (hemostasis), today announced that the company has completed enrolment of its pivotal Phase III clinical trial…

Related to: ProFibrix

Santaris Pharma A/S - The New England Journal of Medicine Publishes Marked and Long-Lasting Antivira

March 27, 2013 – The First MicroRNA-Targeted Drug to Enter Clinical Trials Hørsholm, Denmark/San Diego, California — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the publication of study results…

Related to: Santaris Pharma

Definiens establishes Advisory Board

March 26, 2013 – Munich, Germany – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy,…

Related to: Definiens

uniQure Makes MIT Technology Review’s 50 Disruptive Companies List

March 20, 2013 – CAMBRIDGE, MA, Amsterdam, the Netherlands — uniQure has been identified in the field of biomedicine as one of 2013’s 50 Disruptive Companies, MIT Technology Review’s annual list of the world’s most innovative technology companies. The honorees are nominated by MIT Technology Review’s…

Related to: uniQure

Chroma Therapeutics - Tosedostat OPAL Study in Acute Myeloid Leukaemia Published in the Lancet

March 4, 2013 – Oxford – Chroma Therapeutics Limited announced today that The Lancet Oncology has published the results of the OPAL Study, a Phase 2 study of two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). Tosedostat is a novel, oral…

Related to: Chroma Therapeutics

Ablynx Successfully Raises €31.5 Million, in Total €45 Million Placed

February 28, 2013 – REGULATED INFORMATION GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, announces today that it has raised €31.5 million through a private placement of new shares via an accelerated bookbuilding…

Related to: Ablynx

Definiens Appoints Former Roche Histopathology Head as Chief Medical Officer

February 27, 2013 – Munich, Germany – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, announced the appointment of renowned surgical and anatomical pathologist Dr. Ralf Huss as Chief Medical Officer (CMO). Professor Huss brings significant expertise…

Related to: Definiens

ABLYNX and Spirogen Enter into a Research Collaboration Focusing on Toxin-Nanobody Drug Conjugates in Cancer

February 25, 2013 – GHENT, Belgium and LONDON, United Kingdom, 25 February 2013 - Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines…

Related to: Ablynx

ABLYNX - ALX-0061, Shows Excellent 24 Week Safety and Efficacy Results in a Phase II Clinical Trial

February 13, 2013 – ACR20, ACR50 and ACR70 scores of up to 100%, 75% and 63% respectively Up to 75% of patients in DAS28 remission Attractive safety profile at all administered doses No anti-drug antibodies detected No disease progression as determined by MRI radiography GHENT, Belgium - Ablynx…

Related to: Ablynx

Agendia: Study Shows Half of Early-Stage Breast Cancer Patients May Safely Avoid Chemotherapy

February 4, 2013 – MammaPrint Test Accurately Predicts Breast Cancer Recurrence;  In First Prospective, Outcome-Based Study of Its Kind   IRVINE, CA and AMSTERDAM, THE NETHERLANDS – The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat…

Related to: Agendia

Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone

January 3, 2013 – Oxford – Chroma Therapeutics Limited announced today that GlaxoSmithKline (GSK) has approved the progression of Chroma’s novel macrophage-targeted HDAC inhibitor, CHR-5154, towards human clinical development subject to regulatory approval, triggering an undisclosed milestone payment…

Related to: Chroma Therapeutics

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy
  • SFDR Disclosure